Pioglitazone companion diagnostic - Takeda/Zinfandel

Drug Profile

Pioglitazone companion diagnostic - Takeda/Zinfandel

Alternative Names: AD4833/TOMM40

Latest Information Update: 05 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda; Zinfandel Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 16 May 2018 Takeda terminates a phase III trial for Alzheimer's disease (Diagnosis) in USA, Australia, Switzerland and United Kingdom due to lack of efficacy of the drug (PO) (NCT02284906)
  • 25 Jan 2018 Takeda terminates a phase III trial based on a planned interim futility analysis in Alzheimer's disease (Diagnosis) in United Kingdom, USA, Australia, Germany, Switzerland and Italy (PO) (NCT01931566)
  • 06 Sep 2017 Phase III development is ongoing for Alzheimer's disease (Diagnosis) in USA, Australia and United Kingdom (NCT02284906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top